IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS

Neurology

Volumn 60, Issue 1, 2003, Pages 52-57

  Waubant, E ^b   Goodkin, D ^b   Bostrom, A ^b   Bacchetti, P ^b   Hietpas, J ^b   Lindberg, R ^a   Leppert, D ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GADOLINIUM; GELATINASE A; GELATINASE B; METHYLPREDNISOLONE; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; BETA1A INTERFERON; DIAGNOSTIC AGENT; INTERFERON BETA SERINE; INTERFERON BETA-1B;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BLOOD; MIDDLE AGED; PREDICTION AND FORECASTING;

DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GADOLINIUM; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PREDICTIVE VALUE OF TESTS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0037435501     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.60.1.52     Document Type: Article

References (33)

1. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
2. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996;3:895-904.
3. Docherty AJP. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. TIBTECH 1992;10:200-207.
4. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113:1477-1489.
5. Welgus HG, Campbell EJ, Cury JD, et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzymes profile, regulation, and expression during cellular development. J Clin Invest 1990;86:1496-1502.
6. Conca W, Willmroth F. Human T lymphocytes express a member of the matrix metalloproteinase gene family. Arthritis Rheum 1994;37:951-956.
7. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
8. Leppert D, Waubant E, Galardy R, Bunnett N, Hauser S. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389.
9. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: a longitudinal clinical and MRI study. Brain 1999;122:191-197.
10. Waubant E, Goodkin D, Gee L, et al. Serum levels of matrix metalloprotease-9 (MMP-9) and tissue inhibitor of MMP-type 1 (TIMP-1) predict MRI activity in relapsing multiple sclerosis. Neurology 1999;53:1397-1401.
11. Maeda A, Sobel R. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300-309.
12. Anthony DC, Ferguson B, Matyzack MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997;23:406-415.
13. Trojano M, Avolio C, Liuzzi GM, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-1408.
14. Waubant E, Gee L, Miller K, Stabler G, Goodkin D. Interferon beta-1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis. J Interferon Cytokine Res 2001;21:181-185.
15. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
17. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
19. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.
20. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DPTA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991;41:1219-1222.
21. Woods RP, Mazziotta JC, Cherry SR. Rapid automated algorithm for aligning and reslicing PET Images. J Comput Assist Tomogr 1992;16:620-633.
22. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17:536-546.
23. Lichtinghagen R, Seifert T, Kracke A, Marckmann S, Wurster U, Heidenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 1999;99:19-26.
24. Leppert D, Waubant E, Burk MR, Oksenberg J, Hauser S. Interferon beta-1b inhibits gelatinase secretion and in vivo migration of human T-cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:244-250.
25. Stüve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863.
26. Lindberg R, De Groot C, Montagne L, et al. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 2001;124:1743-1753.
27. Creange A, Chazaud B, Plonquet A, et al. IFN-beta decreases adhesion and transmigration capacities of lymphocytes in Guillain-Barré syndrome. Neurology 2001;57:1704-1706.
28. Özenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Frederickson S, Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with INF-β. J Neuroimmunol 2000;108:236-243.
29. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001;50:443-451.
30. Kouwenhoven M, Ozenci V, Gomes A, et al. Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes. J Autoimmun 2001;16:463-470.
31. Johnston J, Zhang K, Silva C, et al. HIV-1 tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 2001;49:230-241.
32. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH. T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 2001;124:2203-2214.
33. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998;121:2327-2334.